论文部分内容阅读
目的观察重组人白细胞介素-11(rhIL-11)治疗恶性血液病化疗后血小板减少症的临床疗效和副反应。方法应用自身对照方法,对20例恶性血液病患者分为对照期单用化疗、观察期化疗后加rhIL-11,rhIL-11的用量1500万U/d,连续6～15d,观察血小板最低值、持续天数及不良反应。结果观察期血小板最低值高于对照期(P<0.05),血小板低于20×109/L持续天数少于对照期(P<0.05)。结论 rHIL-11可降低恶性血液病化疗引起血小板下降幅度及血小板持续下降的时间,疗效尚可,安全性高。
Objective To observe the clinical efficacy and side effects of recombinant human interleukin-11 (rhIL-11) in the treatment of thrombocytopenia after chemotherapy for malignant hematological diseases. Methods Twenty patients with hematologic malignancies were divided into two groups: control chemotherapy alone and rhIL-11 plus 15 million U / d for 6-15 days after chemotherapy. The lowest platelet count , The number of days and adverse reactions. Results The lowest value of platelet in the observation period was higher than that in the control period (P <0.05). The duration of platelet less than 20 × 109 / L was less than that in the control period (P <0.05). Conclusion rHIL-11 can reduce the extent of thrombocytopenia caused by chemotherapy-induced hematologic malignancies and the duration of platelet decline. The therapeutic effect is good and safe.